TransCode Therapeutics Open Letter to Shareholders
Rhea-AI Summary
TransCode Therapeutics (NASDAQ: RNAZ) has issued an open letter to shareholders regarding an upcoming Special Meeting on November 22. The company is seeking shareholder authorization for a potential reverse stock split to maintain Nasdaq listing compliance. The split would only be implemented if the stock fails to maintain a $1.00 per share closing price for any ten-day period before December 31, 2024.
Management emphasizes this measure is important for maintaining Nasdaq listing, which they consider critical for raising needed capital to continue clinical trials and operations. The company warns that delisting would likely have a material adverse effect on company and stock value.
Positive
- None.
Negative
- Company at risk of Nasdaq delisting due to non-compliance with minimum bid price
- Urgent need to raise additional capital for clinical trials and operations
- Potential reverse stock split may be necessary, which typically indicates financial distress
- Management admits uncertainty about positive news occurrence or its impact on stock price
News Market Reaction 1 Alert
On the day this news was published, RNAZ declined 2.85%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company:
Dear Shareholders,
At our upcoming Special Meeting to be held November 22, shareholders are being asked to authorize our Board of Directors to effect a reverse split — only if the Board determines that doing so is necessary as described below.
Many shareholders rightly ask why this request. Some believe that the potential announcement of additional positive clinical data or other good news will favorably impact our stock price. However, there is no assurance that any good news will occur, will occur by the deadline required, or that the stock will rise after any such positive announcement(s).
A reverse split is NOT something directors or management wishes to do — we all hope it won’t be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing did so on the condition that our shareholders authorize a reverse split — should one be necessary. The reverse split will not be necessary if our stock closes at
If our stock does not meet this Nasdaq requirement, and we do not have your vote in favor of the reverse split, Nasdaq will delist our stock. A Nasdaq delisting would in all likelihood have a material adverse effect on the value of our company and the value of your stock.
Our assessment boils down to this: your vote is your decision about whether you support our efforts to maintain our Nasdaq listing. Given our need to raise additional capital as soon as possible to continue the clinical trial and other operations, we believe having our stock remain on Nasdaq is critical to raising the needed capital.
TransCode’s management and directors are unanimously determined to maintain our Nasdaq listing. This is why we need you to authorize the reverse split, with all of us hoping that we will not have to implement this decision.
We call for your understanding and greatly appreciate your support.
Your Board and Management
For more information, please contact:
TransCode Therapeutics, Inc.
Tania Montgomery-Hammon, Business Development
tania.montgomery@transcodetherapeutics.com
FAQ
When is TransCode Therapeutics (RNAZ) Special Meeting scheduled?
What is the deadline for RNAZ to meet Nasdaq's minimum bid requirement?
Why is RNAZ considering a reverse stock split?
What minimum stock price does RNAZ need to maintain for Nasdaq compliance?
